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Cognitive neuroscience and brain imaging
Abstract
Imaging technologies have experienced rapid progress and are currently used widely both in medical
diagnostics and in research. Imaging beyond X-ray and standard MRI became established in recent
years. The extended set of imaging methodologies available allows methods to be selected according to
the actual needs or even the combination of different imaging principles to obtain further improved
read-outs. The symposium consisted of four overview lectures. Three speakers from academia and one
speaker from industry described different techniques, recent developments and future needs from
various perspectives in the lectures entitled: Non-Invasive Imaging in Biomedical Research: Annotating
Structure with Molecular Information; Molecular Imaging with PET Tracers and Animal PET Scanners;
Nuclear (PET- and SPECT-) Imaging Agents from Research to Approval (Perspectives from a Pharma
Company Working on in vivo Diagnostics); Cognitive Neuroscience and Brain Imaging.
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imaging. These parameters depend on the 
tissue microstructure, and hence contain 
structural information. Consequently, these 
imaging techniques have been primarily 
used to study the normal and pathological 
anatomy. 
Image quality is assessed by two crite-
ria: Spatial resolution and image contrast. 
From a practical point of view, resolution 
is given by the smallest structure in the im-
age that can be unambiguously identified. 
In the digital era, resolution is commonly 
given as the dimension of a picture element 
(pixel) or volume element (voxel). The ul-
timate limit of spatial resolution achievable 
depends on the intrinsic physical mecha-
nisms underlying the imaging process. For 
instance, for MRI spatial information is in-
evitably lost due to diffusion of water mol-
ecules in the course of the measurement 
process, the mean free diffusion length be-
ing of the order of a few micrometers. In 
Non-Invasive Imaging in Biome-
dical Research: Annotating Struc-
ture with Molecular Information
Markus Rudin
In the Beginning There Was 
 Structural Imaging
When around 1900 Wilhelm Röntgen 
developed a photographic plate showing 
the first X-ray image of his wife’s hand 
he could not have dreamed of the success 
story biomedical imaging has undergone 
since. In the course of the last century es-
sentially all ‘windows to the body’, i.e. 
spectral ranges for which absorption of ra-
diation by tissue is low, have been exploited 
for imaging. Contrast in images arises from 
different properties of the tissue: scattering 
of X-rays at electrons for X-ray, magnetic 
properties of (hydrogen) nuclei for magnet-
ic resonance imaging (MRI), or tissue spe-
cific compressibility values for ultrasound 
doi:10.2533/chimia.2006.805 
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practical terms, intrinsic limits are hardly 
reached for any imaging method and reso-
lution is governed by instrumental factors 
and the inherent sensitivity of the imaging 
modality, which can be increased by spa-
tial averaging thereby degrading resolution 
(Fig. 1). Contrast or rather the contrast-to-
noise ratio (CNR) defines how well adja-
cent structures might be discriminated.
It was soon recognized that contrast 
can be altered by administration of suitable 
agents, molecules containing heavy ele-
ments (iodine) for X-ray, compounds with 
unpaired electrons for MRI. Alternatively, 
when administering compounds containing 
a metastable radionuclide, which decays 
upon emission of γ-quanta or positrons, 
and detecting emanating radiation using a 
suitable detection device (gamma camera, 
single photon emission computer tomog-
raphy SPECT, positron emission tomogra-
phy PET) the distribution of the radiolabels 
within the tissue can be reconstituted. Simi-
lar experiments can be carried out using flu-
orescent dyes. These contrast-enhanced or 
tracer based imaging approaches, besides 
enhancing contrast, offer a new range of 
applications: by measuring signal changes 
dynamically, i.e. as a function of time, they 
provide information on physiological and 
metabolic processes in a spatially resolved 
manner. Many of these functional readouts 
such as tissue blood flow, glucose metabo-
lism, have become indispensable tools in ra-
diology and nuclear medicine departments 
as sensitive indicators of tissue state.
Annotating Structural with 
 Molecular Information
Classical imaging yields morphological 
and physiological information. These ap-
plications have largely defined its role as 
a diagnostic tool, pathologies being iden-
tified as deviation from normal anatomy 
or by altered physiological parameters. In 
addition to the detection and characteriza-
tion of pathologies, the techniques can be 
used for monitoring disease progression, 
for stratification of patient groups, and for 
the evaluation of the response to therapeutic 
interventions. 
Morphological and physiological aber-
rations, however, are the result of abnormal 
molecular processes and it is a reasonable 
hypothesis that quantitative mapping of 
these events in vivo might increase both 
the sensitivity and the specificity of diag-
nostic tools. In addition to structural and 
functional information, ‘molecular’ imag-
ing methods provide readouts on levels of 
transcription and translation products, on 
critical molecules involved in signal trans-
duction, and/or on protein–protein interac-
tions (Fig. 2).
The potential impact of such techniques 
on biomedical research will be significant, 
as diagnostic tools, for the identification of 
patient amenable to a specific therapeutic 
intervention, and for the identification and 
characterization of biomarkers with predic-
tive quality with regard to clinical outcome 
(disease progression or therapeutic effi-
cacy). Similarly basic biomedical research 
will benefit from the quantitative assess-
ment of a molecular process in the intact 
organism with all regulatory processes in 
place, enabling studies at the system level. 
Spatial resolution and CNR define how 
well a specific structure can be identified. 
Yet the two quantities are inversely related: 
the better the spatial resolution the worse 
the CNR is. This is particularly relevant 
Figure 1
Fig. 1. High-resolution structural MRI of mouse brain in vivo (left) and of fixed brain specimen (right). 
Both data sets were collected with same MRI measurement protocol but different spatial resolution 
(voxel dimension = 100 × 100 × 300 µm3 and 60 × 60 × 60 µm3). Images were acquired in 12 min (in 
vivo) and 6 h (ex vivo), the higher resolution in the ex vivo image could only be achieved upon increas-
ing the sensitivity by data averaging. For comparison, the ultimate resolution limit, the free diffusion 
path length is less than 1 µm for the experimental parameters used in the experiment.
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Figure 2
Fig. 2. Molecular imaging techniques provide information on receptor densities (gene expression) and 
receptor occupancy by a ligand/drug molecule, on the activation of signal transduction pathways by 
probing the expression levels of pathway molecules or by assessing protein–protein interactions, and 
on the functional consequences thereof such as the induction of down-stream gene expression or 
structural, physiological and metabolic responses.
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with regard to molecular imaging applica-
tions. Tissue concentrations of critical bio-
molecules are low, typically sub-nanomolar, 
requiring the use of highly sensitive imag-
ing modalities such as nuclear imaging, in 
particular SPECT and PET, and optical im-
aging. However, these techniques offer lim-
ited spatial resolution due to the underlying 
physical principles; in the case of PET due 
the finite positron lifetime, errors in photon 
detection, and finite dimension of detector 
system, while in the case of optical imag-
ing geometrical information is lost due to 
the diffusive propagation of light photons in 
tissue. Multimodal techniques, combining 
two or three complementary imaging mo-
dalities, allow some of these deficiencies 
to be overcome. The high spatial resolution 
provided by MRI or CT imaging can be 
combined with high sensitivity readouts de-
rived from PET or optical imaging, thereby 
annotating anatomical structures with func-
tional or molecular information. Moreover, 
multimodal imaging will allow the simul-
taneous recording of multiple parameters, 
i.e. tissue is characterized by a parameter 
profile instead of individual measures. This 
will enhance the specificity of the assay and 
provide unique mechanistic information.
Target-specific Assays
The key step in molecular imaging is 
the design of a target-specific probe that 
selectively provides cellular or molecular 
information. It is beyond the scope of this 
article to describe the various approaches 
in detail. The reader is referred to the litera-
ture [1–3]. Nevertheless, some basic design 
features and advantages/disadvantages of 
the respective approaches shall be briefly 
outlined.
The standard target-specific probe con-
sists of a reporter moiety that is linked to 
a target-specific carrier molecule (Fig. 3). 
Reporter molecules can be paramagnetic 
complexes or super-paramagnetic nanopar-
ticles for MRI, fluorescent dyes or quantum 
dots for optical imaging, or radionuclides 
for nuclear imaging (PET and SPECT). 
Target-specific moieties are low-molecular 
weight receptor ligands or enzyme sub-
strates, antibodies and fragments thereof, 
or oligonucleotides. 
Problems in designing target-specific 
probes are similar to those encountered in 
drug development. A molecular probe must 
have a high target affinity (in the nanomo-
lar range), high target specificity, good 
bioavailability (membrane permeability) 
and favourable pharmacokinetic properties 
(the non-bound fraction should be rapidly 
eliminated to achieve a high target-to-back-
ground contrast), and a good safety profile. 
In addition, it should be detectable with 
high sensitivity at non-pharmacological 
doses; it should yield a signal when only a 
small fraction of targets is occupied. This 
might require specific signal amplification 
to be designed into the probe (see [1]). Ob-
viously, the development of such probes, in 
particular for clinical use is difficult. Most 
molecular probes that are currently used 
in the clinics are based radio-labelling of 
known receptor ligands, thereby exploiting 
the inherent high sensitivity of the nuclear 
imaging methods.
Well-characterized examples are imag-
ing ligands targeting somatostatin recep-
tors (SSTRs). SSTRs are membrane-bound 
receptors belonging to the glycoprotein 
coupled receptor (GPCR) superfamily. 
Their endogenous ligand is somatostatin, a 
neuropeptide with a short plasma half life. 
SSTRs are highly expressed in neuroendo-
crine tumours and as such represent attrac-
tive targets for a tumour-specific imaging 
probe. A metabolically stabilized somato-
statin analogue, octreotide, has been used as 
targeting moiety to which various reporter 
groups have been coupled (see Fig. 3). Ad-
ministration of these ligands led to highly 
specific enrichment at the tumour site in 
patients suffering from neuro-endocrine 
tumours [4] and in animal models thereof 
[5]. An inherent problem when using such 
probes is the differentiation between signals 
arising from specifically bound (= target) 
from those of non-specifically bound or un-
bound reporter molecules (= background). 
The target-to-background ratio depends on 
the pharmacokinetic properties of the label 
and is a function of time; hence, optimal tim-
ing of the imaging experiment is essential.
The use of activatable probes alleviates 
this issue: high target-to background ratio 
is achieved by the fact that detection of 
the signal requires an interaction with the 
molecular target. Probe molecules that do 
not undergo activation by the target will 
remain ‘silent’. Activatable probes under-
go structural modifications and thereby 
change their biophysical properties upon 
interaction with the target. Magnetic relax-
ivity and fluorescent parameters critically 
depend on the molecular structure. For ex-
ample, coordination of (tissue) water mol-
ecules to the inner coordination-sphere 
of paramagnetic metal complexes (e.g. 
of Gd(iii)) is essential for affecting the 
contrast in MR images by enhancing the 
relaxation of proton spins; critical factors 
determining relaxation efficiency are the 
number of free inner-sphere coordination 
sites, the water exchange rates, the overall 
molecular rotation (which depends on the 
molecular size). All these parameters can 
be influenced by a chemical reaction such 
as a cleavage of a molecular residue [6]. 
Similarly organic fluorophore properties 
depend on the molecular structure such 
as the length of the conjugated π-electron 
system. Intermolecular processes between 
fluorophores such as fluorescence quench-
ing or fluorescence resonance energy trans-
fer (FRET) depend on the intermolecular 
distance and hence, fluorescence intensity 
can be modulated by modulating this dis-
tance r (∝ r6). Obviously radioisotopes 
cannot be used as reporter for activatable 
probes: nuclear decay occurs irrespective 
of the chemical environment of the radio-
nuclide.
 
 
  
     
 

   
  
 
 
  

 
   
Figure 3
Fig. 3. Design of a target-specific probe combining as essential elements a signal-generating reporter 
with a targeting moiety. As additional feature, a cargoing element might be attached that enhances 
intra-cellular delivery of the construct.
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Examples of activatable probes are pro-
tease sensors [7]. They consist of a macro-
molecular biocompatible backbone (e.g. m-
pegylated poly-l-lysine), to which a peptide 
motif, which is recognized and cleaved by 
the target protease, is coupled. Adjacent to 
the cleavage site two fluorescent reporters 
are attached; due to their proximity fluores-
cence is effectively quenched as long as the 
construct remains intact. Upon cleavage of 
the target peptide, the fluorophore groups 
are released, their intermolecular distance 
increases and a strong fluorescence is ob-
served. The difference in fluorescence in-
tensity between the bound and cleaved state 
are two to three orders of magnitude both in 
vitro and in vivo.
A third generic strategy is the develop-
ment of reporter gene assays, which are 
widely used basic molecular biology tools 
that are now made available for in vivo im-
aging. Reporter proteins are expressed un-
der the control of a target gene promoter 
sequence that regulates the expression of 
the target gene; hence, expression levels 
of the reporter gene product are used as a 
surrogate for the levels of the target pro-
tein. Different strategies for inserting the 
reporter gene may be applied: replacement 
of the target by the reporter gene leading 
to a functional knockout, expression as a 
target-reporter fusion protein using a pep-
tidic linker, or co-expression of target and 
reporter gene. An interesting application of 
the use of reporter genes are assays prob-
ing protein–protein interaction such as the 
two-hybrid system [8][9], the protein frag-
ment complementation assay [10] or pro-
tein splicing [11][12], which provide highly 
relevant information on the activation of 
signal transduction pathways. Typical re-
porter genes used for in vivo imaging are 
listed in Table 1.
Challenges in Biomedical 
 (Molecular) Imaging
Imaging has matured to an indispen-
sable technology in various fields of bio-
medical research and novel approaches 
providing molecular and cellular readouts 
are being developed at a rapid pace. Some 
of them will be translated into diagnostic 
clinical tools, while others are designed for 
fundamental research. In any case, a signifi-
cant number of technical challenges have to 
be overcome.
Increase in Sensitivity
Imaging should enable full three-di-
mensional coverage of the target tissue with 
both high spatial and temporal resolution, 
as well as high sensitivity, i.e. high CNR 
or signal-to-background ratio. Yet, these re-
quirements are mutually exclusive; increas-
ing resolution will inherently compromise 
CNR. Hence, increasing sensitivity per unit 
time of current approaches as defined by
is essential. It can be increased by either 
increasing the terms in the numerator or by 
decreasing the terms in denominator. Vari-
ous strategies are being pursued. 
a)  Increasing the signal
 A trivial approach is to increase of the 
concentration C of the reporter moiety, 
e.g. by increasing the dose administered 
or by improving its pharmacokinetic 
properties. Limitations are dictated by 
potential biological interference of ex-
ogenous labels. More attractive is the 
development of marker molecules with 
increased signal output S per individual 
reporter entity. This is an area of active 
research in MRI and optical imaging. 
The efficiency of MR contrast agents 
increases when the relaxivity per para-
magnetic centre is enhanced; similarly, 
fluorescence properties such as quan-
tum yield or excitation/emission wave-
length should be optimized to attain 
maximal signal intensity and minimal 
background interference due to tissue 
autofluorescence. A different avenue is 
specific for MRI: due to the low energies 
involved in MRI, only small population 
differences exist between ground and 
excited spin state at room temperature, 
Thus, only a small fraction of the nucle-
ar spins (typically 10 ppm) contribute 
to the signal detected, i.e. MRI is inher-
ently insensitive. Several orders of mag-
nitude in sensitivity can be gained by 
increasing spin polarization, generating 
a so-called hyperpolarized state, an area 
of active research [19]. Amplification of 
the signal can also achieved by increas-
ing the number of the reporter groups 
associated to each targeting moiety, e.g. 
attachment of N fluorescent groups to an 
antibody will lead to a N-fold increased 
fluorescence output assuming that the 
reporter groups behave independently, 
which is in general not the case. Finally, 
SNR per unit time can also be improved 
by decreasing the acquisition time Tacq 
per image allowing for a higher number 
of averages Naverages to be collected per 
unit time. A large number of fast sam-
pling data strategies have been devel-
oped recently, in particular for MRI. 
b)  Decreasing noise
 The noise figure σnoise in the image is 
governed by two principal noise sources: 
noise generated by the sample to be im-
aged, σn,sample, and the noise generated 
by the detection device, σn,detector. Sam-
ple noise is intrinsically linked to the 
measurement principle and, therefore, 
unavoidable: reducing sample noise 
would also reduce the signal. Thermal 
noise is an important contributor to the 
detector noise figure; hence reducing the 
temperature of the detection devices can 
lead to significant noise reduction and 
correspondingly to increases in SNR/
time. This has been realized both for 
optical imaging by using cooled charge-
coupled devices (CCDs) or in MRI by 
using cooled radiofrequency receiver 
coils [20]. However, probe cooling will 
enhance SNR only in cases for which 
the variance of detector noise is at least 
comparable to that of sample noise.
Dealing with Complexity
Biological systems are inherently com-
plex and simultaneous measurement of 
multiple parameters would be highly at-
tractive. As different modalities provide 
complementary information, their com-
bination might enable a comprehensive 
characterization of tissue, enhancing the 
diagnostic sensitivity and specificity. To-
day, the combination PET/CT linking func-
tional/metabolic to anatomical information 
Table 1. Reporter gene systems developed for in vivo imaging
Reporter gene product Reporter ligand Imaging modality Reference
Herpes simplex virus-1 thymidine 
     kinase (HSV1-tk)
[131I] FIAU
[124I] FIAU
SPECT
PET
[13]
[14]
β-galactosidase EgadMe MRI [7]
Mutated transferrin receptor MION MRI [15]
Firefly luciferase d-luciferin Bioluminescence [16]
Fluorescent protein (GFP) – Fluorescence [17][18]
FIAU: 2’-fluoro’-2’-deoxy-1-β-d-arabinofuranosyl-5-iodo-uracil; EgadMe: (1-(2-(β-galactopyrano
syloxy)propyl)-4,7,10-tris(carboxymethyl)-1,4,7,10-tetraazacyclododecane) gadolinium(III); MION: 
monocrystalline iron oxide nanoparticles
2/11
averages
acqnoise
voxel N
T
VS
C
time
SNR v V  (1) 
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has matured to a clinical standard. Further 
multiplexed techniques are currently under 
development. Hierarchical imaging, i.e. 
combining imaging across length scales 
will provide a biochemical/biophysical 
rationale for signal/contrast changes ob-
served. For example, an MRI tissue pa-
rameter is given as the weighted average 
of the contributions of tissue constituents 
comprised in a voxel of typically 100 × 100 
× 500 µm3. Combination with microscopy 
techniques might allow analysis of the mi-
cro-structure underlying the macroscopic 
observables. Complex biological processes 
might be analyzed at various levels. As an 
example, neuronal activation pattern might 
be analyzed as networks of interacting cer-
ebral domains (whole brain level), excita-
tion processing within a network composed 
of individual neurons (neuron cluster level), 
or at the sub-cellular level.
Quantification
Quantitative understanding of imag-
ing readouts is critical in order to derive 
biomedically relevant information. This 
requires on the one hand the development 
or improvement of software tools for image 
registration, i.e. the exact alignment of im-
ages collected in different sessions or using 
different modalities, and segmentation, i.e. 
the identification of various tissue classes. 
Extracting biological information from im-
aging data sets is dependent on the basic 
understanding of the underlying physi-
ological, metabolic or molecular processes. 
Sophisticated tissue models will help to 
rationalize imaging data. Multiplexed tech-
niques will characterize tissue by parameter 
profiles (signatures) rather than individual 
parameters, which will be analyzed using 
statistical tools analogous to those used in 
e.g. metabonomics studies [21][22].
Imaging Agents
The key success factors in molecular 
imaging are probes/assays that provide 
target-specific information. Their develop-
ment is closely related to drug-development 
(see above) and there is considerable syn-
ergy potential between the development of 
therapeutics and diagnostics. 
Molecular imaging is currently still in 
its infancy; many of the applications to date 
are of the proof-of-principle type and the 
tools have not yet been developed to a stage 
where they can be used in a routine research 
or clinical setting. Consequently, many of 
the tools developed to date are far from be-
ing optimal; novel assays are required to 
tackle novel questions. It is, however, be-
yond doubt that imaging and in particular 
molecular imaging will make a significant 
impact on biomedical research. 
Molecular Imaging with PET 
 Tracers and Animal PET Scanners
Pius August Schubiger
Molecular Imaging and Positron 
Emission Tomography (PET)
Molecular imaging has become a very 
popular term in medicine. In the literature 
and at scientific meetings images are pre-
sented under the term ‘molecular’ – irrespec-
tive of the imaging method (CT, US, MRI, 
BLI or PET) and the information gained 
from the imaging method. However some 
methods will lead to e.g. structural images, 
whereas molecular imaging methods make 
molecular processes visible, quantifiable 
and traceable over time in a live animal or 
human [23]. Therefore I would define mo-
lecular imaging as ‘in vivo imaging of bio-
logical processes with appropriate specific 
molecular probes’. 
So the real challenge in molecular imag-
ing is the search for the ‘optimal’ molecu-
lar imaging probes followed by the search 
for the appropriate (imaging) method. Un-
derstanding biology at the molecular level 
needs molecules which are part of the bio-
logical processes underlying normal or dis-
eased states. Imaging methods have been 
established using nuclear, optical and MRI 
imaging probes as explained by M. Rudin in 
the previous section. The choice of a certain 
imaging modality depends primarily on the 
specific question to be addressed. Answer-
ing those questions requires methods with 
specific properties on spatial resolution, 
sensitivity and specificity. The strength and 
weakness of various methods are discussed 
in many reviews (see e.g. [2][24]). In Table 
2 some high-resolution small animal imag-
ing systems are compared. It is obvious, 
that only PET has the sensitivity needed to 
visualize most interactions between physi-
ological targets and ligands such as neuro-
transmitters and brain receptors. Therefore, 
if the question concerns monitoring drug 
distribution, pharmacokinetics and phar-
macodynamics, PET is the only choice as 
a nuclear imaging technique for most or-
gans.
Positron emission tomography is based 
on the annihilation of a positron. If a posi-
tron is emitted from a radionuclide it loses 
first its kinetic energy and then combines 
with an electron. The result of this proc-
ess is annihilation of both particles through 
emission of two gamma rays. These gamma 
rays are emitted in opposite direction and 
can be detected coincidentally by PET de-
tectors (see Fig. 4). Due to the ring geom-
etry of the PET detectors and reconstruc-
tion computer programs it is possible to 
transform the registered gamma rays into 
a three dimensional representation of the 
radioactivity distribution. The main con-
stituents of most biological molecules are 
carbon, nitrogen and oxygen. The incorpo-
ration of positron-emitting radionuclides 
such as carbon-11, nitrogen-13 or oxygen-
15 with physical half-lives of 20, 10 and 2 
minutes into such biomolecules leads then 
to optimal PET probes or PET radiophar-
maceuticals because they are chemically 
indistinguishable from the non-labelled 
counterparts. 
Development of New Molecular PET 
Probes 
Once a desired PET molecular probe 
(PET ligand) is defined and synthesized, an 
in vivo animal test can successfully proceed 
only if a number of prerequisites have been 
fulfilled. These conditions for a PET ligand 
for the imaging of central nervous system 
(CNS) receptors are discussed below.
Selectivity/High Affinity for the Receptor 
(Ki or Kd < 10
–9M)
The equilibrium dissociation constant 
(Kd) of a drug receptor complex is the con-
centration of drug that occupies or binds 
to 50% of available receptor population. 
By definition, affinity is the reciprocal of 
the equilibrium dissociation constant and 
is ideally highest for the target site to be 
imaged. Considering that the concentration 
of binding sites (Bmax) for most brain re-
ceptors is rather low (nano- to femtomoles 
per milligram tissue), PET ligands should 
have binding affinities in the subnanomolar 
Table 2. Small animal imaging modalities
Imaging method Spatial resolution Temporal resolution Sensitivity
Ultrasound 50 µm >10 ms 10–3 Mol
CT 50 µm >300 ms 10–3 Mol
MRI 100 µm >50 ms 10–5Mol
MRS 1 mm (?) >60 ms 10–5 Mol
BLI 1–3 mm (depth!) 1 ms
PET >1 mm >1 s 10–9–10–12 Mol
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range. But too high an affinity can render a 
PET radiopharmaceutical useless because 
its uptake may become blood flow depend-
ent instead of being dependent of the rate 
of binding. 
Specific Radioactivity
Specific radioactivity refers to the 
amount of radioactivity per unit mass of a 
radiopharmaceutical. Unlike radioligands 
used only for in vitro binding assays, ra-
dioligands used for in vivo brain receptor 
imaging must be prepared in high specific 
radioactivities so that only a small per-
centage of the total number of available 
binding sites is occupied by the radiolig-
and. Low specific radioactivity may lead 
to saturation of the binding sites which 
may result in pharmacological effects or 
toxicity. 
Metabolism and Position of Label
 Since PET cannot discriminate between 
signals from parent radioligand and radiola-
belled metabolites, it is essential that PET 
ligands do not undergo rapid metabolism 
over the period of PET measurements. It 
has therefore to be verified that radioactive 
metabolites that are formed in the course 
of data acquisition do not contaminate the 
PET signals. The position of the radiolabel 
in a molecule is also another crucial factor 
and has to be considered very carefully dur-
ing the planning of the synthetic approach 
since the loss of the radiolabel in a molecule 
by metabolic degradation will limit its use-
fulness as a PET ligand. 
Blood–Brain Barrier Permeability
For a CNS radiopharmaceutical to be 
useful as an imaging agent, it must be li-
pid soluble and should readily pass the 
blood–brain barrier (BBB). The octanol/
water partition coefficient, P, is often used 
as a predictor for BBB penetration. The P 
values can be computed or experimentally 
measured and log P values between 2 and 3 
are generally considered optimal. The crite-
rion necessarily holds for diffusion-mediat-
ed transport systems but not for specialized 
active transport systems as it is the case for 
amino acids. 
Clearance Rate and Binding to 
 Proteins
Also of importance are rapid clearance 
rates from blood and non-specific binding 
sites. A low binding of radioligand to plas-
ma proteins is essential since only the free 
fraction of radioligand in plasma is availa-
ble for diffusion out of the vascular space. 
A first example concerns potential 
PET-ligands for the metabotropic gluta-
matergic receptor subtype 5 (mGluR5). 
Table 3 shows the structures of potential 
PET ligands with their respective binding 
affinities and lipophilicity values. This is 
a selection of some of the ligands we re-
cently synthesized and evaluated [25][26]. 
The only compound which is selective and 
shows high affinity is [11C]-ABP688. It is 
the first known PET-ligand displaying an in 
vivo distribution pattern consistent with the 
known regional density of mGluR5. Fig. 5 
shows an animal PET study in a rat brain. 
The results indicate that this compound has 
the potential to become a valuable tracer 
for imaging the mGluR5 distribution in hu-
mans using PET. Furthermore it could be of 
great value for the selection of appropriate 
doses of clinically relevant candidate drugs 
that bind to the mGluR5.
The second example is about the uptake 
of [18F]-FECNT (2β-carbomethoxy-3β-/4-
chlorophenyl)-8-(2-fluoroethyl)-nortro-
pane), a dopamine-transporter ligand in the 
striatum of mice. Parkinson’s disease (PD) 
is characterized by a progressive degenera-
tion of nigrostriatal neurons and depletion 
of dopamine in the striatum. This striatal 
degeneration can be analyzed non-invasive-
ly by small animal PET imaging using the 
DAT tracer [18F]-FECNT in a mouse model 
of PD. Furthermore, such an experimental 
Principle of PET
data
acquisition
detectors
electron
positron 511 keV
photons PET-scan
coincidence
electronics
18F-nucleus
Figure 4Fig. 4. The principle of PET
PET studies of [11C]-ABP688 uptake 
in a rat brain
ID: 29.4 MBq (SA: 23 GBq/umol, inj. mass: 1.3 nmol)
Data reconstructed with bin size 0.5mm from 0-30min post injection
hippocampishi
st striatum
bulbus
cerebellum
lacrimal gland
Cingulate cortex
Figure 5
Fig. 5. PET studies of [11C]-ABP688 uptake in a rat brain
Table 3. Development of a molecular PET-probe: structures of some mGluR5 PET ligands
Development of a Molecular PET-Probe:
Structures of some mGluR5 PET Ligands
Ligand Structure MW
(g/mol)
LogPcalc
(LogDexp)
KD
(nM)
IC50
(nM)
MPEP
6-methyl-2-
(phenylethynyl)-pyridine 193.24 3.77 34
M-MPEP
2-methyl-6-
((methoxyphenyl)
ethynyl)-pyridine
223.27 3.64 3.4
M-FPEP
2-methyl-6-(3-fluoro
phenylethynyl)
pyridine
211.23 3.93(2.7)
1.4 + 1.1 9
ABP688
3-(6-methyl-pyridin-2-
ylethynyl)-cyclohex-2-
enone O-methyl-oxime
239.31 2.44(2.4)
1.7 + 0.2 3
N
N
O 11CH3
N
11CH3
F
N
N
O
11CH3
Table 3
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approach can be applied to develop novel 
drugs against PD. 
Fig. 6 shows representative coronal 
slices of the head of three different mice 
injected with the [18F]-FECNT: a control 
mouse (left), a lesioned mouse (middle) 
and a lesioned mouse that was treated with 
a drug (right).
Animals were lesioned with MPTP (2 
× 15 mg/kg) and received the drug in the 
drinking water. All PET images were ob-
tained by adding data from 1–31 min post 
injection and are normalized to the inject-
ed dose per body weight. Drug treatment 
leads to a clear recovery of [18F]-FECNT 
uptake in the striatum of MPTP-lesioned 
mice, thus demonstrating the drug’s effi-
cacy to restore dopaminergic neurotrans-
mission.
Nuclear (PET- and SPECT-) 
 Imaging Agents from Research 
to Approval (Perspectives from a 
Pharma Company Working on in 
vivo  Diagnostics)
Matthias Bräutigam
What was celebrated as a sensation 
over 100 years ago with the discovery of 
the X-ray has since developed into a highly 
specialized field of medicine: diagnostic 
imaging. It allows physicians to diagnose 
diseases at an early stage and thus begin a 
suitable treatment. Nowadays, additional 
diagnostic procedures such as computer 
tomography (CT), magnetic resonance im-
aging (MRI), ultrasound and nuclear diag-
nostic methods are available in addition to 
the classic X-ray. 
Schering has been a pioneer in the de-
velopment of contrast media for these tech-
nologies. Today, Schering’s research fo-
cuses on new and innovative approaches in 
the fields of magnetic resonance imaging, 
computer tomography, optical and molecu-
lar imaging.
Molecular imaging technologies based 
on radioactive isotope techniques such as 
PET (Positron Emission Tomography) and 
SPECT (Single Photon Emission Computed 
Tomography) gain more and more relevance 
for the in vivo characterization of biologi-
cal processes on the cellular and molecular 
level. They bear the potential for an earlier 
and more specific diagnosis (e.g. staging), 
an earlier monitoring of therapeutic inter-
ventions and a monitoring of a ‘broader’ 
and ‘more specific’ set of pathophysiologi-
cal markers (e.g. glucose metabolism, pro-
liferation, apopotosis, expression of erb B2 
receptor, expression of estrogen receptor, 
specific distribution of [18F]-herceptin and 
[18F]-fluoroestradiol).
FDG ([18F]-fluoro-deoxyglucose) rep-
resents an example for a clinically avail-
able nuclear PET imaging reagent. Due to 
the limited half live of the [18F]-isotope (2 
h), very challenging technological prob-
lems had to be solved to obtain finally the 
approval for its clinical use: ultra rapid 
production of [18F]-fluoro-deoxyglucose 
including isotope production in a cyclo-
tron, most rapid chemical synthesis, pu-
rification, analytics and QA release (Fig. 
7). The fact that only micro-doses of la-
belled tracer have to be applied clinically 
facilitates regulatory approval; e.g. <100 
µg (0.08 µg for FDG-PET) is injected 
(<1/100th of the dose calculated to yield a 
pharmacological effect). FDG is currently 
approved for diagnostics in a broad set of 
different cancer types and for Alzheimer’s 
disease.
123I labelled scFv(L19), a recombinant 
human antibody fragment with sub-na-
nomolar affinity for the Extra-Domain B 
(EDB) of Fibronectin is an example of a 
clinically used nuclear SPECT compound 
(Fig. 8). It serves as marker of angiogen-
esis, the growth of new blood vessels in 
tumour tissue. ED-B expression is relevant 
in primary tumours of various histotypes, 
thus the Extra-Domain B (EDB) Fibronec-
tin marker can be used successfully in clear 
cell carcinoma of the kidney, invasive ductal 
carcinoma and invasive lobular carcinoma 
associated with breast cancer, in adenocar-
cinoma associated with prostate cancer and 
in oral squamous cell carcinoma.
The cost of commercialising a new agent 
for diagnostic imaging is substantially lower 
than that for a new (cold) therapeutic drug 
(in the range of $100–200 million) with a 
total development time of 8–10 y. A block-
buster agent (most of which have been on 
the market for some time) has peak sales of 
$200–400 million. Obviously, it is more at-
tractive to develop an imaging agent for a 
wide range of applications, the development 
of an agent for a rare disease is possible only 
if high selling prices can be achieved. 
• control • lesioned
• MPTP 2x15mg/kg
• treated
• MPTP 2x15mg/kg sc
[18F]-FECNT PET in 
Healthy, Lesioned and Treated Animals
Figure 6
Fig. 6. [18F]-FECNT PET in healthy, lesioned and treated animals
PET Tracer Production
 Very fast manufacture and QC/QA - 50 % loss of F-18 in 2 h!
 Example of a PET Tracer manufacturing process: FDG
Proton
Purified FDG                         Single Unit Doses and QA release
Purification                                        Fill/Finish
50-60% yield in 25 min from EOB Approx. 1 h from EOB
Isotope Production     Isotope Isolation  Specific Product Synthesis
Chromatography                         RP Dispening Unit
Fig. 7. PET tracer production
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In the future, we expect a more close 
collaboration between pharma and diag-
nostics divisions and imaging agents will 
not only be used as diagnostic agents to de-
tect and monitor specific diseases but also 
as markers to speed up the development of 
therapeutic drugs and to manage patient 
care post approval.
Cognitive Neuroscience and 
Brain Imaging
Hanns Möhler and Alumit Ishai 
Introduction 
Cognitive neuroscience is the attempt 
to delineate the neural substrates which 
correlate with higher cognitive brain func-
tions such as language, emotions, memory 
or consciousness. Complex brain functions 
involve the operation of multiple brain ar-
ED-B Fibronectin Targeted Imaging
I-123 Labeled SPECT Compound
I-123
Radionuclide γ radiation
 L19
 human recombinant L19 
scFv derivative that binds
to ED-B fibronectin
 Radiolabeling of the scFv
derivative via tyrosin
residues
 Isotope: I-123 (cyclotron-
produced γ emitter)
Fig. 8.
eas encompassing distributed neuronal net-
works which act in concert. The distributed 
architecture of the brain can be visualized 
by functional brain imaging technologies. 
As an example, functional magnetic reso-
nance imaging (fMRI) studies of visual per-
ception, imagery and memory are outlined 
below. In the future, however, new methods 
will be needed to monitor the functional 
connectivity between brain areas to gain 
further insights into the operation of the 
human brain. 
What is Cognitive Neuroscience? 
In 1895, a little-known Viennese neu-
ropsychiatrist named Sigmund Freud, 
wrote a work entitles ‘A project for a sci-
entific psychology’ in which he proposed 
that the cognitive mechanisms of normal 
and abnormal mental phenomena could 
be explained through orderly and rigorous 
study of brain systems. The empirical ba-
sis for this endeavour was, however, very 
small. Although the ‘Neuron-doctrin’ had 
recently been published, it was not known 
how neurons interact; neither the synapse 
nor the electrophysiological properties of 
nerve cells were known. Freud abandoned 
both the project and neuropsychiatry [27]. 
This example illustrates the difficulty in re-
lating mental phenomena to a neuronal sub-
strate at the time, due to the lack of a con-
ceptional and methodological framework. 
In the subsequent 50 years, psychology and 
familiar prototype novel, similar novel, ambiguous novel, different
face-selective regions in the fusiform gyrus
-1
0
1
2
3
P S A D
PE
Left
P S A D
Right
L R
8.0
T-values
* *
4.8
Fig. 9. Subjects memo-
rized prototypes of por-
traits by Renoir. Four 
days later, a memory 
retrieval session was 
conducted in the MR 
scanner. The familiar 
prototypes (P) were 
mixed with new exem-
plars that were visually 
similar (S), ambiguous 
(A) or different (D), and 
subjects indicated 
whether they had seen 
each picture before. 
The fMRI data analysis 
revealed activation 
in the lateral fusiform 
gyrus, a face-respon-
sive region. Within this 
region, familiar proto-
types evoked stronger 
activation than all the 
new exemplars, regard-
less of their visual simi-
larity [29].
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neuroscience went their own separate ways. 
In various schools of psychology, behav-
iour was studied purely as an input–output 
pattern of observable aspects. In this view 
the brain itself was simply considered as a 
black box. The operation of the brain was 
not taken into account, as if the process by 
which information is transformed in the 
brain cannot influence behaviour. On the 
other hand, the discipline of neurobiology 
focused on the efforts to understand the 
structure and function of neural circuits, in 
particular with regard to sensory and mo-
tor systems based on the conceptual frame-
work of neuronal signalling of individual 
cells and networks. With the advent of mo-
lecular biology, advanced morphology and 
techniques for studying the activity of sin-
gle cells, the first correlations between cog-
nitive processes and the pattern of neuronal 
firing in specific brain areas were found. 
In the seventies and eighties, cognitive 
psychology acknowledged that internal 
representations are an essential component 
of behaviour. It was recognized that with-
out direct access to the neural substrates 
of internal representations it appeared dif-
ficult, if not impossible, to understand the 
path from perception to action. As a con-
sequence, the way behaviour was studied 
changed both in experimental animals and 
in humans. The focus had now shifted to the 
question of information processing in the 
brain that mediates behaviour. 
The Distributed Architecture of the 
Brain 
Today, the two lines of research, cog-
nitive psychology and neurobiology, have 
merged into a new discipline termed cog-
nitive neuroscience. In the frame-work of 
cognitive neuroscience, a cooperation takes 
place between psychology, neuropsychol-
ogy, psychiatry, neurology, systems physi-
ology, cell biology and molecular biology. 
This interdisciplinary approach enables 
the scientific study of memory, perception, 
action, language, emotion and conscious 
awareness. 
In this setting, imaging technologies 
(see M. Rudin and A. Schubiger) take centre 
stage in the cognitive neurosciences. Func-
tional MRI is a technique that permits the 
localization of regions in the human brain 
that are activated during cognition, with 
fine spatial and temporal resolutions (mil-
limetres and seconds, respectively). Due 
to its non-invasive nature, fMRI is particu-
larly useful for studying the neural basis of 
higher cognitive phenomena, such as visual 
imagery, which are not easily simulated in 
animal models (see below). Modern imag-
ing technologies are therefore a great step 
forward in explaining behavioural, men-
tal and psychological phenomena through 
processes of concerted local brain activi-
ties. A distributed functional architecture 
of the brain became apparent. 
The Representation of Visual 
 Memory 
Most if not all brain functions involve 
various brain areas acting in concert. A vis-
ual memory task is outlined below to illus-
trate the distributed architecture of the brain. 
Recognition memory depends on the visual 
similarity between a known prototype and 
a novel exemplar. For instance, the paint-
ings of Picasso’s blue period share certain 
characteristics which permit us to decide 
whether a new picture which is presented to 
us belongs to this period or not. To analyse 
how recognition memory is represented in 
the brain, a functional magnetic resonance 
imaging (fMRI) study was recently per-
formed [28]. In an encoding session, sub-
jects were instructed to memorize paintings 
(portraits by Modigliani and Renoir, land-
scapes by Pissarro and Van Gogh, abstract 
paintings by Kandinsky and Mirò) and were 
explicitly told that the prototypes from each 
painter belong to a category of paintings 
with a unique style (Fig. 9). Each picture 
was presented on the centre of a computer 
screen for 5 sec and was repeated four times 
to enable deep encoding. Four days later, 
the subjects performed a memory retrieval 
task in the MR scanner. The familiar proto-
types from each painter were randomly pre-
sented among various new exemplars. The 
new pictures were either visually similar to 
the familiar prototypes, ambiguous, or dis-
similar (Fig. 9). Each picture was presented 
for 3 sec and the subjects pressed a button to 
indicate whether they had seen the picture 
before (‘yes’ for the prototypes, ‘no’ for the 
new exemplars). The fMRI results revealed 
activation within a distributed cortical net-
work that included visual, limbic, parietal 
and prefrontal regions. 
Visual Brain Areas 
Perception of portraits, landscapes and 
abstract paintings evoked activation in 
face- and object-selective regions in the 
visual cortex. In the lateral fusiform gyrus, 
a face-responsive region, portraits elicited 
stronger activation than landscapes and 
abstract paintings. In the medial fusiform 
and para-hippocampal gyri, regions that 
respond to houses and places, respectively, 
landscapes evoked stronger activation than 
portraits and abstract paintings. In the pos-
terior fusiform gyrus, abstract paintings 
evoked stronger activation than portraits 
and landscapes. Within these face- and ob-
ject-selective regions, familiar prototypes 
of portraits and abstract paintings evoked 
stronger responses than the new exemplars 
(Fig. 9). Taken together, the patterns of acti-
vation observed in the visual cortex indicate 
that explicit encoding of categorical paint-
ings results in stimulus-specific representa-
tions. 
Attention-related Brain Areas 
Activation in attention-related regions 
in parietal cortex, namely the intraprietal 
sulcus and the superior parietal lobule, re-
vealed stronger responses to the familiar 
prototypes than to the new exemplars of 
portraits, landscapes and abstract paintings. 
Moreover, activation within these regions 
was reduced with decreased similarity 
between the new exemplars and the pro-
totypes. The enhanced activation evoked 
by the prototypes and the reduced activity 
elicited by the visually different exemplar 
suggest that the attention-related regions 
process the segmentation of old from new 
items. 
Memory-related Brain Areas 
Recognition memory of prototypes of 
paintings revealed activation in multiple 
memory-related areas with distinct patterns 
of response: in the caudate, insula, and an-
terior cingulate cortex, the familiar proto-
types elicited stronger activation than the 
new items, whereas in the precuneus, supe-
rior temporal and superior frontal gyri the 
new, visually different exemplars evoked 
stronger activation. Finally, in the hippoc-
ampus, the similar items evoked weaker ac-
tivation than the other novel exemplars. In 
summary, the results show that recognition 
memory is mediated by a distributed corti-
cal network where activation is modulated 
by the visual similarity between familiar 
prototypes and novel exemplars. Face- and 
object-selective regions in the visual sys-
tem store stimulus-specific representations, 
attention-related regions in parietal cortex 
detect the familiar prototypes and memory-
related areas classify novel exemplars as a 
match or a mismatch. 
Visual Perception and Visual 
 Imagery 
Complex pictorial information can be 
represented and retrieved from memory 
as mental visual images. Functional brain 
imaging studies have shown that visual 
perception and visual imagery share com-
mon neural substrates. The type of memory 
(short- or long-term) that mediates the gen-
eration of mental images and the effects of 
focal attention to features of visual mental 
images were addressed in another fMRI 
study [29]. Famous faces were used to lo-
calize the visual response during perception 
and to compare the responses during visual 
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imagery generated from short-term mem-
ory (subjects memorized specific pictures 
of celebrities before the imagery task) and 
imagery from long-term memory (subjects 
imagined famous faces without seeing spe-
cific pictures during the experimental ses-
sion). Visual perception of famous faces 
activated face-selective regions in the infe-
rior occipital gyrus, lateral fusiform gyrus, 
superior temporal sulcus, and the amygda-
la. Although the pictures were grey-scale 
photographs of contemporary Hollywood 
celebrities with neutral expressions and 
the task was passive viewing, bilateral ac-
tivation in the amygdala was observed in 
all subjects, probably due to the affective 
component of viewing good-looking faces. 
Interestingly, small subsets of these face-
selective regions were activated during 
visual imagery. These results suggest that 
sensory representations of faces stored in 
face-selective regions in the visual cortex 
and the amygdala are reactivated during the 
generation of visual images. The view that 
the neurons that ‘see’ are also the neurons 
that ‘remember’ is supported by early evi-
dence that sensory regions in the temporal 
lobe are associated with memory retrieval 
[30]. 
Visual Imagery, Memory, and 
 Attention 
Visual imagery of famous faces acti-
vated a network of regions composed of bi-
lateral calcarine, hippocampus, precuneus, 
intraparietal sulcus, and the inferior frontal 
gyrus. Within these regions, imagery gener-
ated from short-term memory evoked more 
activation than imagery from long-term 
memory. Thus, when subjects were pre-
sented with specific pictures of celebrities 
and memorized them prior to the imagery 
task, the brain activity during imagery was 
stronger, suggesting that maintaining a 
trace in a ‘working memory buffer’ for sev-
eral seconds likely mediates the generation 
of visual images. Regardless of memory 
type, focusing attention on features of the 
imagined faces (e.g. eyes, lips, or nose) re-
sulted in increased activation in the right 
intraparietal sulcus and right inferior fron-
tal gyrus. These results suggest differential 
effects of memory and attention during the 
generation and maintenance of mental im-
ages of faces. 
Taken collectively, these findings re-
vealed that visual imagery of famous faces 
may be implemented by content-related 
activation in small subsets of visual cor-
tex, and ‘top-down’ mechanisms in parietal 
and frontal cortex that mediate the retrieval 
of face and object representations from 
long-term memory and their maintenance 
through visual imagery.
Outlook
Imaging technologies permit the iden-
tification of areas of neuronal activity. In 
the future, methods will have to be devel-
oped to visualize the flow of information 
between brain areas in governing behav-
iour. The connectivity between neural 
networks will have to be monitored in 
order to understand how the different neu-
ronal networks interact in the distributed 
architecture of the brain. Knowledge on 
the task-dependent dynamics of the op-
erational connections between brain areas 
will be needed.
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